Project information
Project manager
Ian Nicholls
Other project members
Camilla Mohlin, Per Nilsson, Sofia Somajo.
Participating organizations
Linnaeus University, AroCell AB, Attana AB, Capitainer AB, Luma-Metall AB, Region Kalmar
Financier
KK-Stiftelsen
Timetable
1 July 2023–30 June 2027
Subject
Biomedicine Chemistry (Faculty of Health and Life Sciences)
More about the project
Clinical diagnostics play a crucial role in the detection, diagnosis, and treatment of diseases. Accurate and timely diagnostic tests allow healthcare providers to identify health status and determine the most appropriate course of treatment. In addition, clinical diagnostics play a key role in public health efforts to monitor and control the spread of infectious diseases.
The rapidly increasing demand for new, more sensitive, and more robust clinical diagnostic tools for use by healthcare providers and for self-monitoring is driven by society’s need for shortening waiting times and reducing the costs of healthcare.
Improved monitoring methods that can provide more reliable and cost-efficient diagnoses can enable earlier diagnoses, and sometimes facilitate lifesaving interventions in, e.g., cancer or borrelia.
This project aims to develop highly sensitive and robust diagnostic platforms and accommodating sampling technologies for important medical conditions, to provide knowledge for health providers, patients, decision makers, and researchers.
We aim to realize our overarching objective through four sub-projects, targeting:
- Cancer biomarker detection – small cell lung cancer (Project manager: Ian Nicholls)
- Virus-related diseases: e.g. COVID-19 and hepatitis (Project manager: Per Nilsson)
- Enhanced bacterial infection diagnosis – Lyme disease & E.coli related urinary tract infections (Project manager: Sofia Somajo)
- Biosensor-based histology – glaucoma & macular degeneration (Project manager: Camilla Mohlin)
The project is part of:
Staff
